[1]盛凌黎,曹子怡,郭小平,等.加味陈氏糖肾方治疗糖尿病肾脏病G3-4A1-3期合并脂代谢紊乱临床研究[J].陕西中医,2025,46(2):192-196.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.009]
　SHENG Lingli,CAO Ziyi,GUO Xiaoping,et al.Clinical study of modified CHEN's Tangshen decoction in the treatment of diabetic kidney disease G3-4A1-3 complicated with lipid metabolism disorder[J].,2025,46(2):192-196.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.009]
点击复制

加味陈氏糖肾方治疗糖尿病肾脏病G3-4A1-3期合并脂代谢紊乱临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年2期
页码:
192-196
栏目:
临床研究
出版日期:
2025-02-05

文章信息/Info

Title:
Clinical study of modified CHEN's Tangshen decoction in the treatment of diabetic kidney disease G3-4A1-3 complicated with lipid metabolism disorder
作者:
盛凌黎1; 2; 曹子怡3; 郭小平1; 李文诗1; 孙家乐1; 王 琳1
(1.上海中医药大学附属龙华医院肾病二科,上海 200032; 2.澳门科技大学中医药学院,澳门 999078; 3.陕西中医药大学第一临床医学院,陕西 咸阳 712046)
Author(s):
SHENG Lingli1; 2; CAO Ziyi3; GUO Xiaoping1; LI Wenshi1; SUN Jiale 1; WANG Lin1
(1.Nephropathy Department Ⅱ,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China; 2.Faculty of Chinese Medicine,Macao University of Science and Technology,Macao 999078,China; 3.The First Clinical Medical College of Shaanxi University of Chinese Medicine,Xianyang 712046,China)
关键词:
糖尿病肾脏病;  脂代谢紊乱;  加味陈氏糖肾方;  肾功能;  尿蛋白;  中医症候积分
Keywords:
Diabetic kidney disease;  Lipid metabolism disorder;  Modified CHEN's Tangshen decoction;  Renal function;  Urinary protein;  TCM symptom score
分类号:
R 587.1
DOI:
DOI:10.3969/j.issn.1000-7369.2025.02.009
文献标志码:
A
摘要:
目的:观察加味陈氏糖肾方治疗糖尿病肾脏病G3-4A1-3期合并脂代谢紊乱的临床疗效。方法:共纳入72例糖尿病肾脏病G3-4A1-3期合并脂代谢紊乱的患者,在西医常规疗法基础上,对照组35例患者给予安慰剂治疗,观察组37例患者给予加味陈氏糖肾方治疗,比较两组患者血糖、肾功能、血脂、尿蛋白指标及中医症候积分、临床综合疗效,采用Pearson相关分析探讨血脂水平与24 h尿蛋白的相关性。结果:治疗前两组患者各项指标均未见统计学差异(P>0.05)。治疗后,观察组患者空腹血糖(FBG)、血肌酐(Scr)及血尿素氮(BUN)水平,血清甘油三酯(TG)、总胆固醇(TC)及低密度脂蛋白(LDL-C)水平,24 h尿蛋白、尿微量白蛋白浓度、尿α1微球蛋白及尿β2微球蛋白水平,中医症候积分均明显低于对照组(P<0.05); 血清高密度脂蛋白(HDL-C)水平明显高于对照组(P<0.05)。Pearson相关分析显示,TC、LDL-C均与24 h尿蛋白呈正相关(P<0.05)。观察组患者临床综合疗效总有效率为83.78%,明显高于对照组患者的60.00%(P<0.05)。结论:加味陈氏糖肾方能够有效降低糖尿病肾脏病G3-4A1-3期合并脂代谢紊乱患者尿蛋白水平,稳定患者肾功能,调节血糖水平和脂代谢紊乱,进而延缓糖尿病肾脏病进展。
Abstract:
Objective:To observe the clinical effect of modified CHEN's Tangshen decoction in the treatment of diabetic kidney disease G3-4A1-3 stage complicated with lipid metabolism disorder.Methods:This prospective included 72 patients with G3-4A1-3 stage diabetic kidney disease complicated with lipid metabolism disorder.On the basis of the standard therapy,35 patients in the control group were given placebo treatment,and 37 patients in the observation group were given the modified CHEN's Tangshen decoction treatment.Blood glucose,renal function,blood lipid,urinary protein indexes,TCM symptom score and clinical comprehensive effect were compared between the two groups.Pearson analysis was used to explore the correlation between blood lipid level and 24 h urinary protein.Results:Before treatment,there were no obvious differences in all indexes between the two groups(P>0.05).After treatment,compare with the control group,the levels of fasting blood glucose(FBG),serum creatinine(Scr)and blood urea nitrogen(BUN),serum triglyceride(TG),total cholesterol(TC)and low density lipoprotein(LDL-C),24 h urinary protein,urinary microalbumin concentration,urinary α1 microglobulin and urinary β2 microglobulin,and TCM syndrome score in the observation group were obviously lower(P<0.05),and the serum high density lipoprotein(HDL-C)level was obviously higher(P<0.05).TC and LDL-C were positively correlated with 24 h urinary protein(P<0.05).The total effective rate in the observation group was 83.78%,which was obviously higher than 60.00% in the control group(P<0.05).Conclusion:Modified CHEN's Tangshen decoction can effectively reduce the urinary protein level of patients with G3-4A1-3 stage diabetic kidney disease complicated with lipid metabolism disorder,stabilize renal function,regulate blood glucose level and lipid metabolism disorder,and then delay the progression of diabetic kidney disease.

参考文献/References:

[1] 王臣廷,刘婷,吕翠君,等.己酮可可碱联合缬沙坦治疗糖尿病肾病疗效及对患者肾功能、血管内皮生长因子的影响[J].陕西医学杂志,2024,53(7):966-969.
[2] ZOU Y,ZHAO L,ZHANG J,et al.Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease[J].Ren Fail,2022,44(1):562-570.
[3] 邓婷婷.糖尿病肾脏病患者血脂异常与尿蛋白关系研究[J].中国中西医结合肾病杂志,2019,20(6):527-529.
[4] SAMSU N.Diabetic nephropathy:Challenges in pathogenesis,diagnosis,and treatment[J].Biomed Res Int,2021,2021:1497449.
[5] 中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南(2021年版)[J].中华糖尿病杂志,2021,13(8):763-785.
[6] 中华医学会内分泌学分会脂代谢学组.中国2型糖尿病合并血脂异常防治专家共识(2017年修订版)[J].中华内分泌代谢杂志,2017,33(11):925-936.
[7] 李桂霞,翟晓丽,黄艺,等.蛭龙胶囊对糖尿病肾脏病中医症候积分、肾功能指标及炎症因子的干预研究[J].中国处方药,2023,21(7):155-159.
[8] 李勇,王丹,井丽红,等.扶阳保肾方对糖尿病肾病合并Ⅳ型心肾综合征患者血清指标的影响[J].陕西中医,2024,45(3):365-368.
[9] 蒋琳,陆璧,张彦,等.血管生成抑制蛋白1、血清沉默信息调节因子1、血栓素-B2在2型糖尿病肾病中的水平变化及与白蛋白尿进展的关系分析[J].陕西医学杂志,2024,53(1):46-50.
[10] CHEN Y,LEE K,NI Z,et al.Diabetic kidney disease:challenges,advances,and opportunities[J].Kidney Dis(Basel),2020,6(4):215-225.
[11] YANG J,LIU Z.Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy[J].Front Endocrinol(Lausanne),2022,13:816400.
[12] 陈秀娟,刘慧,苏宝印.芪地固肾丸治疗糖尿病肾病Ⅲ期疗效及对患者中医症候积分、肾功能和血清eGFR、CRP水平的影响[J].陕西中医,2024,45(5):634-637.
[13] 杨凯笛,王旭,刘静,等.中药调控脂代谢紊乱治疗糖尿病肾脏病研究进展[J].中药材,2022,45(10):2530-2534.
[14] MIAO M,DENG X,WANG Z,et al.Cardiometabolic index is associated with urinary albumin excretion and renal function in aged person over 60:Data from NHANES 2011-2018[J].Int J Cardiol,2023,384:76-81.
[15] 杨学萍,张岁林,曹为,等.糖尿病肾脏疾病患者血脂异常与尿蛋白关系的临床研究[J].糖尿病新世界,2020,9(17):183-185.
[16] WADA T,MUSO E,MARUYAMA S,et al.Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia[J].Clin Exp Nephrol,2018,22(3):591-596.
[17] MORIYA T,HAYASHI A,MATSUBARA M,et al.Glucose control,diabetic retinopathy,and hemodialysis induction in subjects with normo-microalbuminuric type 2 diabetic patients with normal renal function followed for 15 years[J].J Diabetes Complications,2022,36(1):108080.
[18] 严慧艳,王敬丽,陈晟,等.上海市某社区2型糖尿病患者血脂控制现状分析[J].中国社区医师,2021,37(5):171-172.
[19] JOHANNESEN C D,LANGSTED A,MORTENSEN M B,et al.Association between low density lipoprotein and all cause and cause specific mortality in denmark:Prospective cohort study[J].BMJ,2020,371:4266.
[20] KENI R,SEKHAR A,GOURISHETTI K,et al.Role of statins in new-onset diabetes mellitus:The underlying cause,mechanisms involved,and strategies to combat[J].Curr Drug Targets,2021,22(10):1121-1128.
[21] SEO W W,SEO S I,KIM Y,et al.Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin:A distributed network analysis of 10 real-world databases[J].Cardiovasc Diabetol,2022,21(1):82.
[22] WANG D,WANG L,ZHANG M,et al.Astragalus membranaceus formula for moderate-high risk idiopathic membranous nephropathy:A meta-analysis[J].Medicine(Baltimore),2023,102(9):32918.
[23] HASSAN H M,MAHRAN Y F,GHANIM A M H.Ganoderma lucidum ameliorates the diabetic nephropathy via down-regulatory effect on TGFβ-1 and TLR-4/NF-κB signalling pathways[J].J Pharm Pharmacol,2021,73(9):1250-1261.
[24] ZHANG Z T,GUO N,ZHUANG G D,et al.Metabolic profiling of carbonyl compounds for unveiling protective mechanisms of pueraria lobata against diabetic nephropathy by UPLC-Q-Orbitrap HRMS/MS analysis[J].J Agric Food Chem,2021,69(37):10943-10951.
[25] DENG Y F,HUANG X L,SU M,et al.Hypolipidemic effect of SIPI-7623,a derivative of an extract from oriental wormwood,through farnesoid X receptor antagonism[J].Chin J Nat Med,2018,16(8):572-579.

相似文献/References:

[1]翟蒙藏,张文宗,张 鸣.保元逐瘀护心汤对老年冠心病合并高血压患者血压、心功能及Salusin-β、TNF-α、CRP水平的影响[J].陕西中医,2024,(4):494.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.013]
[2]王 晖,赵文景,孟 元,等.保肾通络方治疗糖尿病肾脏病气阴两虚兼血瘀证疗效及对患者血清isthmin-1水平的影响[J].陕西中医,2025,46(5):620.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.009]
　WANG Hui,ZHAO Wenjing,MENG Yuan,et al.Research of Baoshen Tongluo decoction on serum isthmin-1 of diabetic kidney disease with qi yin deficiency and blood stasis[J].,2025,46(2):620.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.009]

备注/Memo

备注/Memo:
[基金项目]上海市卫生健康委员会卫生行业临床研究专项立项课题(202140371)
更新日期/Last Update: 2025-02-08